255 related articles for article (PubMed ID: 38198112)
21. Pathological Complete Response to Neoadjuvant Chemoimmunotherapy for Early Triple-Negative Breast Cancer: An Updated Meta-Analysis.
Rizzo A; Cusmai A; Massafra R; Bove S; Comes MC; Fanizzi A; Rinaldi L; Acquafredda S; Gadaleta-Caldarola G; Oreste D; Zito A; Giotta F; Lorusso V; Palmiotti G
Cells; 2022 Jun; 11(12):. PubMed ID: 35740985
[TBL] [Abstract][Full Text] [Related]
22. KEYNOTE-522, IMpassion031 and GeparNUEVO: changing the paradigm of neoadjuvant immune checkpoint inhibitors in early triple-negative breast cancer.
Rizzo A; Cusmai A; Acquafredda S; Giovannelli F; Rinaldi L; Misino A; Palmiotti G
Future Oncol; 2022 Jun; 18(18):2301-2309. PubMed ID: 35378995
[TBL] [Abstract][Full Text] [Related]
23. Immune checkpoint inhibitors for triple-negative breast cancer: From immunological mechanisms to clinical evidence.
Farshbafnadi M; Pastaki Khoshbin A; Rezaei N
Int Immunopharmacol; 2021 Sep; 98():107876. PubMed ID: 34146865
[TBL] [Abstract][Full Text] [Related]
24. Immunotherapy for triple-negative breast cancer: Existing challenges and exciting prospects.
Jia H; Truica CI; Wang B; Wang Y; Ren X; Harvey HA; Song J; Yang JM
Drug Resist Updat; 2017 May; 32():1-15. PubMed ID: 29145974
[TBL] [Abstract][Full Text] [Related]
25. Targeted Treatment for High-Risk Early-Stage Triple-Negative Breast Cancer: Spotlight on Pembrolizumab.
Bagegni NA; Davis AA; Clifton KK; Ademuyiwa FO
Breast Cancer (Dove Med Press); 2022; 14():113-123. PubMed ID: 35515356
[TBL] [Abstract][Full Text] [Related]
26. Targeted Therapies for Triple-Negative Breast Cancer.
Lyons TG
Curr Treat Options Oncol; 2019 Nov; 20(11):82. PubMed ID: 31754897
[TBL] [Abstract][Full Text] [Related]
27. Prospect of neoadjuvant/adjuvant immunotherapy in early-stage triple-negative breast cancer.
Hao X; Gao X; Yin S; Jiang Z
Transl Breast Cancer Res; 2023; 4():6. PubMed ID: 38751481
[TBL] [Abstract][Full Text] [Related]
28. Role of Immunotherapy in Breast Cancer.
Jacob SL; Huppert LA; Rugo HS
JCO Oncol Pract; 2023 Apr; 19(4):167-179. PubMed ID: 36608303
[TBL] [Abstract][Full Text] [Related]
29. The landscape of systemic therapy for early stage triple-negative breast cancer.
Lu JY; Alvarez Soto A; Anampa JD
Expert Opin Pharmacother; 2022 Aug; 23(11):1291-1303. PubMed ID: 35818711
[TBL] [Abstract][Full Text] [Related]
30. Immunotherapy Approaches for Breast Cancer Patients in 2023.
Emens LA; Loi S
Cold Spring Harb Perspect Med; 2023 Apr; 13(4):. PubMed ID: 37011999
[TBL] [Abstract][Full Text] [Related]
31. Immunotherapy in Triple-Negative Breast Cancer.
Emens LA
Cancer J; 2021 Jan-Feb 01; 27(1):59-66. PubMed ID: 33475294
[TBL] [Abstract][Full Text] [Related]
32. The Role of Immunotherapy in Triple-Negative Breast Cancer (TNBC).
Michaels E; Chen N; Nanda R
Clin Breast Cancer; 2024 Jun; 24(4):263-270. PubMed ID: 38582617
[TBL] [Abstract][Full Text] [Related]
33. Innate immunity as a target for novel therapeutics in triple negative breast cancer.
Borgovan T; Yanamandra N; Schmidt H
Expert Opin Investig Drugs; 2022 Aug; 31(8):781-794. PubMed ID: 35791862
[TBL] [Abstract][Full Text] [Related]
34. Emerging drugs for the treatment of triple-negative breast cancer: a focus on phase II immunotherapy trials.
Hall PE; Schmid P
Expert Opin Emerg Drugs; 2021 Jun; 26(2):131-147. PubMed ID: 33870839
[No Abstract] [Full Text] [Related]
35. The evolving role of immune checkpoint inhibitors in the treatment of triple-negative breast cancer.
Steiner M; Tan AR
Clin Adv Hematol Oncol; 2021 May; 19(5):305-315. PubMed ID: 33989278
[TBL] [Abstract][Full Text] [Related]
36. Phase II Trial of Neoadjuvant Carboplatin and Nab-Paclitaxel in Patients with Triple-Negative Breast Cancer.
Yuan Y; Lee JS; Yost SE; Li SM; Frankel PH; Ruel C; Schmolze D; Robinson K; Tang A; Martinez N; Stewart D; Waisman J; Kruper L; Jones V; Menicucci A; Uygun S; Yoder E; van der Baan B; Yim JH; Yeon C; Somlo G; Mortimer J
Oncologist; 2021 Mar; 26(3):e382-e393. PubMed ID: 33098195
[TBL] [Abstract][Full Text] [Related]
37. Prospect of immunotherapy in neoadjuvant/adjuvant treatment for early breast cancer.
Miyashita M; Ishida T
Chin Clin Oncol; 2020 Jun; 9(3):28. PubMed ID: 32312056
[TBL] [Abstract][Full Text] [Related]
38. The emerging role of immune checkpoint inhibitors for the treatment of breast cancer.
Howard FM; Villamar D; He G; Pearson AT; Nanda R
Expert Opin Investig Drugs; 2022 Jun; 31(6):531-548. PubMed ID: 34569400
[TBL] [Abstract][Full Text] [Related]
39. Potential Predictive and Prognostic Value of Biomarkers Related to Immune Checkpoint Inhibitor Therapy of Triple-Negative Breast Cancer.
Tan Q; Yin S; Zhou D; Chi Y; Man X; Li H
Front Oncol; 2022; 12():779786. PubMed ID: 35646659
[TBL] [Abstract][Full Text] [Related]
40. Construction and validation of a gene expression classifier to predict immunotherapy response in primary triple-negative breast cancer.
Ensenyat-Mendez M; Orozco JIJ; Llinàs-Arias P; Íñiguez-Muñoz S; Baker JL; Salomon MP; Martí M; DiNome ML; Cortés J; Marzese DM
Commun Med (Lond); 2023 Jul; 3(1):93. PubMed ID: 37430006
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
